Dadun/></a>
				</td>
				<td class= Dadun
   (New user)
Help  | Contact  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Oncología > Inmunoterapia > DA - CIMA - Oncología - Inmunoterapia - Artículos de Revista >

Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies
Authors: Murillo, O. (Oihana)
Arina, A. (Ainhoa)
Tirapu, I. (Íñigo)
Alfaro, C. (Carlos)
Mazzolini, G. (Guillermo)
Palencia, B. (Belén)
Lopez-Diaz-de-Cerio, A. (Ascensión)
Prieto, J. (Jesús)
Bendandi, M. (Maurizio)
Melero, I. (Ignacio)
Keywords: Antibodies, Monoclonal/therapeutic use
Neoplasms/immunology
Issue Date: 2003
Publisher: American Association for Cancer Research
Publisher version: http://clincancerres.aacrjournals.org/content/9/15/5454
ISSN: 1557-3265
Citation: Murillo O, Arina A, Tirapu I, Alfaro C, Mazzolini G, Palencia B, et al. Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies. Clin Cancer Res 2003 Nov 15;9(15):5454-5464.
Abstract
Immunotherapeutic monoclonal antibodies (mAbs) can be defined as those that exert their functions by tampering with immune system cell molecules, causing an enhancement of antitumor immune responses. Some of these antibodies are agonistic ligands for surface receptors involved in the activation of lymphocytes and/or antigen-presenting cells, whereas others are antagonists of mechanisms that normally limit the intensity of immune reactions. Several mAbs of this category have been described to display in vivo antitumor activity in mouse models. Only anti–CTLA-4 (CD152) mAb has entered clinical trials, but the preclinical effects described for anti- CD40, anti-CD137 (4-1BB), anti-CD102 (intercellular adhesion molecule-2), and regulatory T cell-depleting mAbs should lead to their prompt clinical development. Their use in combination with immunizations against tumor antigens has been reported to be endowed with synergistic properties. This new group of antitumor agents holds promise for at least additive effects with conventional therapies of cancer and deserves intensive translational research.
Permanent link: http://hdl.handle.net/10171/18752
Appears in Collections:DA - Medicina - Medicina Interna - Artículos de revista
DA - CIMA - Terapia génica y Hepatología - Inmunología terapia génica - Artículos de revista
DA - CIMA - Oncología - Inmunoterapia - Artículos de Revista
DA - CUN - Hematología y Hemoterapia - Artículos de revista
DA - CUN - Área de Terapia Celular - Artículos de revista
DA - Medicina - Hematología - Artículos de revista

Files in This Item:
File:  Clin Canc Res 2003_9.pdf
Description: 
Size:  235,18 kB
Format:  Adobe PDF
 View / Open 

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.